{"filing":{"accession_number":"0001193125-26-266770","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"d570985d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/d570985d8k.htm"},"events":[{"id":5339,"run_id":4677,"accession_number":"0001193125-26-266770","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Jaguar Health entered into two material equity financing arrangements on June 9, 2026: a $40 million Equity Line of Credit (ELOC) with an accredited investor and a $2 million Preferred Stock Financing with multiple investors including pre-funded warrants. Both transactions involve unregistered or to-be-registered equity issuances that will dilute existing shareholders.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6133,"accession_number":"0001193125-26-266770","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Jaguar Health entered into two material equity financing arrangements on June 9, 2026: (1) a $40 million Equity Line of Credit (ELOC) with an accredited investor providing for future issuance of common stock, and (2) a $2 million Preferred Stock Financing with multiple investors including pre-funded warrants. Both transactions involve unregistered or to-be-registered equity issuances that will dilute existing shareholders. The ELOC includes $800,000 in Commitment Shares and the Preferred Stock Financing includes pre-funded warrants exercisable for additional common shares, representing classic dilutive capital raises typical of small-cap companies in financial need.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:01:12.121067+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6134,"accession_number":"0001193125-26-266770","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of equity securities under Section 4(a)(2) and Regulation D Rule 506 to accredited investors. The filing references Preferred Stock Purchase Agreements and an ELOC Agreement, indicating a private placement of equity securities. Such dilutive issuances are material to investors as they affect ownership structure and capital raising capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:01:12.121067+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5340,"run_id":4677,"accession_number":"0001193125-26-266770","anchor_item_number":"5.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The company filed a Series P Certificate of Designation establishing the terms of a new preferred stock class with 8% annual dividends, liquidation preferences, mandatory and optional redemption provisions, and anti-dilution protections. These structural provisions create contingent obligations that could materially affect the company's capital structure and shareholder value.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6135,"accession_number":"0001193125-26-266770","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This Item 5.03 discloses the Series P Certificate of Designation filed in connection with a preferred stock financing (referenced in Items 1.01 and 3.02). While Item 5.03 typically covers routine bylaw amendments, this disclosure is material because it establishes the terms of a new preferred stock class with significant economic rights—8% annual dividends, liquidation preferences, mandatory and optional redemption provisions, and anti-dilution protections tied to a registration statement. The triggering events and redemption caps create contingent obligations that could materially affect the company's capital structure and shareholder value. This is best classified as \"other_material\" rather than a more specific category, as it is a structural capital event distinct from the underlying financing transaction itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:01:12.121067+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6133,"accession_number":"0001193125-26-266770","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Jaguar Health entered into two material equity financing arrangements on June 9, 2026: (1) a $40 million Equity Line of Credit (ELOC) with an accredited investor providing for future issuance of common stock, and (2) a $2 million Preferred Stock Financing with multiple investors including pre-funded warrants. Both transactions involve unregistered or to-be-registered equity issuances that will dilute existing shareholders. The ELOC includes $800,000 in Commitment Shares and the Preferred Stock Financing includes pre-funded warrants exercisable for additional common shares, representing classic dilutive capital raises typical of small-cap companies in financial need.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:01:12.121067+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-11"},{"id":6134,"accession_number":"0001193125-26-266770","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of equity securities under Section 4(a)(2) and Regulation D Rule 506 to accredited investors. The filing references Preferred Stock Purchase Agreements and an ELOC Agreement, indicating a private placement of equity securities. Such dilutive issuances are material to investors as they affect ownership structure and capital raising capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:01:12.121067+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-11"},{"id":6135,"accession_number":"0001193125-26-266770","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This Item 5.03 discloses the Series P Certificate of Designation filed in connection with a preferred stock financing (referenced in Items 1.01 and 3.02). While Item 5.03 typically covers routine bylaw amendments, this disclosure is material because it establishes the terms of a new preferred stock class with significant economic rights—8% annual dividends, liquidation preferences, mandatory and optional redemption provisions, and anti-dilution protections tied to a registration statement. The triggering events and redemption caps create contingent obligations that could materially affect the company's capital structure and shareholder value. This is best classified as \"other_material\" rather than a more specific category, as it is a structural capital event distinct from the underlying financing transaction itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:01:12.121067+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-11"}]}